TLR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL102714	0.65	17/20
SCHEMBL102391	0.56	17/20
Rolicyprine (SCHEMBL49385)	0.51	13/20
SCHEMBL102706	0.55	8/20
SCHEMBL26445	0.33	5/20
SCHEMBL119456	0.49	4/20
SCHEMBL119459	0.49	4/20
SCHEMBL118173	0.49	4/20
SCHEMBL102381	0.46	4/20
SCHEMBL114432	0.39	4/20
SCHEMBL26006	0.35	4/20
SCHEMBL73717	0.55	3/20
SCHEMBL21003	0.50	3/20
SCHEMBL109880	0.40	3/20
SCHEMBL109881	0.40	3/20
SCHEMBL111415	0.40	3/20
SCHEMBL111416	0.40	3/20
SCHEMBL112093	0.40	3/20
SCHEMBL112094	0.40	3/20
SCHEMBL114110	0.40	3/20

Clinical trials — most relevant to TLR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic	PHASE2/PHASE3	WITHDRAWN
Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis	PHASE2/PHASE3	UNKNOWN
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis	PHASE3	COMPLETED
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age	PHASE2	RECRUITING
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients	PHASE2	RECRUITING
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis	PHASE2	COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients	PHASE1/PHASE2	COMPLETED
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Role of TLR4 in Environmental Asthma	PHASE1	COMPLETED
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.	PHASE1	COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19	nan	COMPLETED
Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation	nan	UNKNOWN
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Role of TLR2 and TLR4 in Stage 2 Periodontitis Patients	nan	COMPLETED
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection	nan	COMPLETED
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Probiotic Intervention on Gut Microbiota and Cognitive Functioning in Older Adults With a Mild Cognitive Impairment	nan	UNKNOWN
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population	nan	RECRUITING
TLR4 Polymorphisms and Risk of Skin Cancer	nan	COMPLETED
Bacteremia in Intensive Care Unit (ICU)	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Neuro-Immune Interactions in the Gut	nan	COMPLETED
Gut Microbiota and Parkinson's Disease	nan	UNKNOWN
Defects in Opsonophagocytosis in Premature Infants	nan	COMPLETED
The Suppression of Toll Like Receptors by Insulin	nan	COMPLETED
Innate Immunity in Allergic Asthma	nan	RECRUITING
Mucins and Toll-like Receptors in Asthma	nan	COMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients	nan	UNKNOWN
Effects of Zeolite + Dolomite on Performance and Acidosis	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TLR2 binder may also engage these)

Protein	Name	Similarity
Q95M53	—	1.000	Q95M53 →
B3Y618	—	1.000	B3Y618 →
B3Y615	—	1.000	B3Y615 →
Q689D1	—	1.000	Q689D1 →
Q6T752	—	1.000	Q6T752 →
B3Y614	—	1.000	B3Y614 →
B3Y613	—	1.000	B3Y613 →
B2LT61	—	1.000	B2LT61 →
B5T267	—	1.000	B5T267 →
Q95LA9	—	1.000	Q95LA9 →
Q2V897	—	1.000	Q2V897 →
Q2PZH4	—	1.000	Q2PZH4 →
B2LT64	—	0.999	B2LT64 →
Q0GC71	—	0.998	Q0GC71 →
Q9R1F8	—	0.998	Q9R1F8 →
B2LT62	—	0.998	B2LT62 →
Q9EPQ1	—	0.997	Q9EPQ1 →
B2LT65	—	0.996	B2LT65 →
Q9QUN7	—	0.994	Q9QUN7 →
Q0ZUL9	—	0.991	Q0ZUL9 →
Q9EPW9	—	0.991	Q9EPW9 →
P58681	—	0.990	P58681 →
Q9DD78	—	0.989	Q9DD78 →
Q9BXR5	—	0.988	Q9BXR5 →
Q6GV17	—	0.988	Q6GV17 →
TLR7	Toll-like receptor 7	0.985	landscape →
TLR1	Toll-like receptor 1	0.982	landscape →
P58682	—	0.977	P58682 →
TLR8	Toll-like receptor 8	0.977	landscape →
A0N0X6	—	0.975	A0N0X6 →